CommercialCoverageMedium impact
08.00.10d, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued policy 08.00.10d covering Luspatercept-aamt (Reblozyl®), a specialty pharmacy drug. This is a commercial policy update that went into effect December 10, 2025, indicating potential changes to coverage criteria or prior authorization requirements for this medication.
Action Required
Immediately: Review the full policy document at the provided URL to identify specific changes to Luspatercept-aamt (Reblozyl®) coverage requirements. Update prior authorization workflows and verify current coverage criteria for commercial patients requiring this medication. Inform providers of any new documentation requirements.